Weekly Investment Analysts’ Ratings Updates for Haemonetics (HAE)

A number of firms have modified their ratings and price targets on shares of Haemonetics (NYSE: HAE) recently:

• 8/11/2025 – Haemonetics was downgraded by analysts at Raymond James Financial, Inc. from a “strong-buy” rating to an “outperform” rating. They now have a $78.00 price target on the stock, down previously from $105.00.
• 8/8/2025 – Haemonetics had its price target lowered by analysts at Mizuho from $90.00 to $70.00. They now have an “outperform” rating on the stock.
• 8/8/2025 – Haemonetics had its price target lowered by analysts at Barrington Research from $95.00 to $86.00. They now have an “outperform” rating on the stock.
• 8/8/2025 – Haemonetics had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $62.00 price target on the stock, down previously from $85.00.
• 8/7/2025 – Haemonetics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $68.00 price target on the stock, down previously from $84.00.
• 7/11/2025 – Haemonetics had its “outperform” rating reaffirmed by analysts at Barrington Research. They now have a $95.00 price target on the stock.
• 7/9/2025 – Haemonetics was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $90.00 price target on the stock.
• 6/26/2025 – Haemonetics is now covered by analysts at Robert W. Baird. They set an “outperform” rating and a $87.00 price target on the stock.
• 6/25/2025 – Haemonetics was upgraded by analysts at Baird R W to a “strong-buy” rating.

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.